OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Aduhelm, a novel anti-amyloid monoclonal antibody, for the treatment of Alzheimer’s Disease: A comprehensive review
Hannah W. Haddad, Garett W. Malone, Nicholas J. Comardelle, et al.
Health psychology research (2022) Vol. 10, Iss. 2
Open Access | Times Cited: 15

Showing 15 citing articles:

Alzheimer's disease pathophysiology in the Retina
Bhakta Prasad Gaire, Yosef Koronyo, Dieu‐Trang Fuchs, et al.
Progress in Retinal and Eye Research (2024) Vol. 101, pp. 101273-101273
Open Access | Times Cited: 25

Guidelines for pharmacotherapy in Alzheimer’s disease – A primer on FDA-approved drugs
Ashvin Varadharajan, Aarjith Damian Davis, Aishwarya Ghosh, et al.
Journal of Neurosciences in Rural Practice (2023) Vol. 14, pp. 566-573
Open Access | Times Cited: 32

Navigating the dementia landscape: Biomarkers and emerging therapies
Shubhrat Maheshwari, Aditya Singh, Valeed Ahmad Ansari, et al.
Ageing Research Reviews (2024) Vol. 94, pp. 102193-102193
Closed Access | Times Cited: 14

Associations between genetically predicted plasma protein levels and Alzheimer’s disease risk: a study using genetic prediction models
Jingjing Zhu, Shuai Liu, Keenan A. Walker, et al.
Alzheimer s Research & Therapy (2024) Vol. 16, Iss. 1
Open Access | Times Cited: 9

Photobiomodulation in Alzheimer’s Disease—A Complementary Method to State-of-the-Art Pharmaceutical Formulations and Nanomedicine?
Laura Marinela Ailioaie, Constantin Ailioaie, Gerhard Litscher
Pharmaceutics (2023) Vol. 15, Iss. 3, pp. 916-916
Open Access | Times Cited: 22

Recombinant Antibody Fragments for Immunotherapy of Parkinson’s Disease
Karen Manoutcharian, Goar Gevorkian
BioDrugs (2024) Vol. 38, Iss. 2, pp. 249-257
Open Access | Times Cited: 5

Current amyloid inhibitors: therapeutic applications and nanomaterial-based innovations
Paula López-García, María M. Tejero-Ojeda, Marisela Morales, et al.
Progress in Neurobiology (2025), pp. 102734-102734
Closed Access

Alzheimer's disease approaches - Focusing on pathology, biomarkers and clinical trial candidates
Jana Hroudová, Zdeněk Fišar
Progress in Neuro-Psychopharmacology and Biological Psychiatry (2024) Vol. 134, pp. 111069-111069
Closed Access | Times Cited: 2

Secretomic changes of amyloid beta peptides on Alzheimer’s disease related proteins in differentiated human SH-SY5Y neuroblastoma cells
Sittiruk Roytrakul, Janthima Jaresitthikunchai, Narumon Phaonakrop, et al.
PeerJ (2024) Vol. 12, pp. e17732-e17732
Open Access | Times Cited: 2

Recombinant Antibody Fragments for Neurological Disorders: An Update
Karen Manoutcharian, Goar Gevorkian
Current Neuropharmacology (2023) Vol. 22, Iss. 13, pp. 2157-2167
Open Access | Times Cited: 2

Impact of Long-Term Dietary High Fat and Eicosapentaenoic Acid on Behavior and Hypothalamic-Pituitary-Adrenal Axis Activity in Amyloidogenic APPswe/PSEN1dE9 Mice
Breanna N. Harris, Mahsa Yavari, Latha Ramalingam, et al.
Neuroendocrinology (2024) Vol. 114, Iss. 6, pp. 553-576
Closed Access

A closed-loop micropump and flow meter for high-precision drug delivery in an implantable neural probe
Mohammad Makhdoumi Akram, Amir Aghajani, Wei Shi, et al.
(2024), pp. 1-4
Closed Access

Recent Advances in Alzheimer’s Disease Treatments with Therapeutic Antibodies to Amyloid-β
Jerry Yang, Aaron B. Bradford
Journal of Student Research (2022) Vol. 11, Iss. 3
Open Access

Page 1

Scroll to top